Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06847191 · ClinicalTrials.gov registry record · Phase 2
NE3107 in Adults With Neurological Symptoms of Long COVID
A Phase 2 study of Long COVID, sponsored by BioVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 208
- Enrollment target
- 20
- Study locations
NCT06847191: Recruiting Phase 2 study of Long COVID, sponsored by BioVie.
NCT06847191 is a Phase 2 study of Long COVID that is actively recruiting participants, run by BioVie. The registered enrollment target is 208 participants, below the 2,184-participant average among 50 other Long COVID trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06847191, a Phase 2 study of Long COVID, is actively recruiting participants, sponsored by BioVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 208 participants
- Enrollment target
- 20
- Study locations
Study Summary
Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. Researchers will compare NE3107 to a placebo (a look-alike substance that contains no drug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID. Participants will: * Take NE3107 or a placebo twice daily for 84 days * Visit the clinic 5 times for checkups and tests and have a follow up phone call
Primary Outcome
\*This study is designed as a signal-seeking proof-of-concept Phase 2 study. The primary outcome is intended for estimation and hypothesis generation rather than formal hypothesis testing. No single endpoint is designated as definitive for study success. Objective computerized neurocognitive testing using Cogstate battery assessing attention, sustained attention, verbal memory, verbal learning, psychomotor function and processing speed. A composite cognitive score is calculated as the mean of st
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NE3107
Study Locations (20)
California
- Stanford University - Palo Alto
- UCSF - San Francisco
Illinois
- Illinois Research Network University of Illinois at Chicago - Chicago
- Northwestern University - Chicago
Texas
- Zenos Clinical Research - Dallas
- University of Texas health Science Center at San Antonio - San Antonio
Colorado
- University of Colorado - Aurora
Connecticut
- Yale University - New Haven
Florida
- Clinical Trial Site - Jacksonville
Georgia
- Centricity Research - Columbus
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT06847191 shows while recruiting
NCT06847191 is an interventional study that assigns participants to a tested intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap, below the 2,184-participant average among 50 other Long COVID trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Long COVID appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06847191 names 20 study sites across 17 states, led by California, Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT06847191 about?
NCT06847191 is a clinical study titled "NE3107 in Adults With Neurological Symptoms of Long COVID". Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fa...
What is the current status of trial NCT06847191?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2025-04-29. Estimated completion is 2026-08.
What conditions does trial NCT06847191 study?
This clinical trial studies the following conditions: Long COVID.
What interventions are being tested in trial NCT06847191?
The interventions under investigation include: Placebo (DRUG), NE3107 (DRUG).
Who is sponsoring clinical trial NCT06847191?
This trial is sponsored by BioVie, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06847191 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06847191's enrollment target sits among peer trials
208 15th of 50 higher than 36 of 50 other Long COVID trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Long COVID trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
RECRUITING · Phase 2
-
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
RECRUITING · Phase 2
-
AT1001 for the Treatment of Long COVID
RECRUITING · Phase 2
-
LIFT: Life Improvement Trial
RECRUITING · Phase 2
-
A Study to Examine Anktiva for the Treatment of COVID-19.
RECRUITING · Phase 2
-
Antiviral Clinical Trial for Long Covid-19
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI